BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32696252)

  • 1. Risk Factors for Cytomegalovirus Reactivation in Lung Transplant Recipients.
    Kwak SH; Lee SH; Park MS; Jeong SJ; Lee JG; Paik HC; Kim YS; Chang J; Kim SY
    Lung; 2020 Oct; 198(5):829-838. PubMed ID: 32696252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.
    Jaamei N; Koutsokera A; Pasquier J; Mombelli M; Meylan P; Pascual M; Aubert JD; Manuel O
    Transpl Infect Dis; 2018 Aug; 20(4):e12893. PubMed ID: 29603543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.
    Forconi C; Gatault P; Miquelestorena-Standley E; Noble J; Al-Hajj S; Guillemain R; Stern M; Hoffmann T; Prat L; Suberbielle C; Masson E; Cesbron-Gautier A; Gaudy-Graffin C; Goudeau A; Thibault G; Ivanes F; Guibon R; Kazma I; Lebranchu Y; Büchler M; Magnan A; Halimi JM; Baron C
    J Heart Lung Transplant; 2017 Mar; 36(3):315-324. PubMed ID: 27751774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients.
    Gardiner BJ; Nierenberg NE; Chow JK; Ruthazer R; Kent DM; Snydman DR
    Clin Infect Dis; 2018 Oct; 67(9):1395-1402. PubMed ID: 29635432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.
    Bhorade SM; Lurain NS; Jordan A; Leischner J; Villanueva J; Durazo R; Creech S; Vigneswaran WT; Garrity ER
    J Heart Lung Transplant; 2002 Dec; 21(12):1274-82. PubMed ID: 12490272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
    Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
    Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-infection of two beta-herpesviruses (CMV and HHV-7) as an increased risk factor for 'CMV disease' in patients undergoing renal transplantation.
    Chapenko S; Folkmane I; Tomsone V; Amerika D; Rozentals R; Murovska M
    Clin Transplant; 2000 Oct; 14(5):486-92. PubMed ID: 11048994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab.
    Jain T; John J; Kotecha A; Deol A; Saliminia T; Revankar S; Chandrasekar P
    Ann Hematol; 2016 Aug; 95(8):1323-7. PubMed ID: 27225264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
    El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
    J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
    Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
    Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretransplant Cytomegalovirus-Specific Cellular Immunity and Risk of Viral Reactivation Following Lung Transplantation: A Prospective Cohort Study.
    Altaf M; Lineburg KE; Crooks P; Rehan S; Matthews KK; Neller MA; Ambalathingal GR; Sinha D; Grant M; Hopkins PMA; Chambers D; Khanna R; Smith C
    J Infect Dis; 2021 Jul; 224(2):312-317. PubMed ID: 33274385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients.
    Santos CA; Brennan DC; Yusen RD; Olsen MA
    Transplantation; 2015 Aug; 99(8):1658-66. PubMed ID: 25675196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus infection in seropositive unrelated cord blood recipients: a study of 349 Korean patients.
    Park M; Lee YH; Lee SH; Yoo KH; Sung KW; Koo HH; Lee JW; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Chung NG; Cho B; Kim HK; Koh KN; Im HJ; Seo JJ; Baek HJ; Kook H; Hwang TJ; Lee JM; Hah JO; Lim YJ; Park JE; Lyu CJ; Lim YT; Chong SY; Oh D;
    Ann Hematol; 2015 Mar; 94(3):481-9. PubMed ID: 25417830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
    Kamar N; Mengelle C; Esposito L; Guitard J; Mehrenberger M; Lavayssière L; Ribes D; Cointault O; Durand D; Izopet J; Rostaing L
    J Med Virol; 2008 Jun; 80(6):1012-7. PubMed ID: 18428146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient.
    Hemmersbach-Miller M; Alexander BD; Pieper CF; Schmader KE
    Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):455-463. PubMed ID: 31758441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.